Senti Bio Posts $4.22M Net Loss in Q1 on Minimal $16K Revenue
SNTI sits 35% above its 52-week low of $0.77 on elevated volume (3.3× avg).
Summary
Senti Biosciences reported Q1 2026 financial results, showing minimal collaboration revenue of $16K and a significant net loss of $4.22 million, or ($0.14) per share. This financial performance is highly material for a company with a market capitalization of approximately $32 million, indicating substantial cash burn. While the article body notes positive FDA feedback for its lead asset SENTI-202, an $8M grant, and facility cost reductions, the headline's focus on the financial results, which are expected to be accompanied by a going concern warning and details of a highly dilutive $40 million convertible note financing in the full 10-Q, points to severe liquidity challenges. Traders will be focused on the company's ability to manage its cash runway and the long-term implications of its financing strategy.
At the time of this announcement, SNTI was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.4M. The 52-week trading range was $0.77 to $3.88. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.